Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) | Synapse
October 20, 2020Open Access
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
With demonstrated noninferiority to TAP, TC is the global first-line standard for advanced endometrial cancer.